RE: RE: I'd love some insight - iCo-007 has been reporducing many desired effects although under controlled conditions and faciliites which are positive signals within phase I and II
- also looking like there is potential for other stage diabetic macular edema treatments should be complementary to iCo-007 (big pharmas may be taking a closer look if truly complementary)
- interim results from iC0-007 are expected this year - might have some early impact to price already as there appear to be some positives
- iCo-008 has some certain risk mitigation with the partnerhsip with Immune Pharmaceuticals -
- potential for grant funding for iC0-009 phase II testing is also positive
- cash is tight given burn rate increasing but is being managed well - will probably need some support to drive phase II DME triial to final data results but $10M equity line is secured and available if and when needed
- hopefully the upward trend continues
regards